Home › Diffuse Scleroderma › Pennsylvania › Philadelphia
Diffuse Scleroderma clinical trials in Philadelphia, PA
4 studies for Diffuse Scleroderma are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
RecruitingPhase 2
- EncompaSSc site in Philadelphia, PA, Philadelphia
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
RecruitingPhase 3
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RecruitingPhase 2/3
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Diffuse Scleroderma trials in other cities
- New York City, NY8 studies
- Ann Arbor, MI7 studies
- Chicago, IL7 studies
- Los Angeles, CA6 studies
- Durham, NC6 studies
- Houston, TX5 studies
- Baltimore, MD5 studies
- Boston, MA5 studies
- Kansas City, KS4 studies
- Pittsburgh, PA4 studies
- New Orleans, LA4 studies
- Charleston, SC3 studies
Other studies in Philadelphia
- Cancer (all types)60 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma26 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.